ATE457724T1 - Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe - Google Patents

Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe

Info

Publication number
ATE457724T1
ATE457724T1 AT04728870T AT04728870T ATE457724T1 AT E457724 T1 ATE457724 T1 AT E457724T1 AT 04728870 T AT04728870 T AT 04728870T AT 04728870 T AT04728870 T AT 04728870T AT E457724 T1 ATE457724 T1 AT E457724T1
Authority
AT
Austria
Prior art keywords
alpha
aminoamide derivatives
inflammatory actives
inflammatory
aminoamide
Prior art date
Application number
AT04728870T
Other languages
English (en)
Inventor
Patricia Salvati
Orietta Veneroni
Elena Barbanti
Fariello Ruggero
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Application granted granted Critical
Publication of ATE457724T1 publication Critical patent/ATE457724T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04728870T 2003-08-25 2004-04-22 Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe ATE457724T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49772203P 2003-08-25 2003-08-25
PCT/IB2004/001574 WO2005018627A1 (en) 2003-08-25 2004-04-22 Alpha-aminoamide derivatives useful as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ATE457724T1 true ATE457724T1 (de) 2010-03-15

Family

ID=34216147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04728870T ATE457724T1 (de) 2003-08-25 2004-04-22 Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe

Country Status (21)

Country Link
US (2) US20070276046A1 (de)
EP (1) EP1658062B1 (de)
JP (1) JP5042625B2 (de)
KR (1) KR101233711B1 (de)
CN (1) CN1842328A (de)
AT (1) ATE457724T1 (de)
AU (1) AU2004266494B2 (de)
BR (1) BRPI0413982A (de)
CA (1) CA2536764C (de)
CY (1) CY1109992T1 (de)
DE (1) DE602004025586D1 (de)
DK (1) DK1658062T3 (de)
ES (1) ES2339021T3 (de)
IL (1) IL173886A (de)
NO (1) NO335245B1 (de)
NZ (1) NZ545502A (de)
PL (1) PL1658062T3 (de)
PT (1) PT1658062E (de)
RU (1) RU2396251C2 (de)
SI (1) SI1658062T1 (de)
WO (1) WO2005018627A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545502A (en) * 2003-08-25 2010-04-30 Newron Pharm Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1557166A1 (de) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate für die Behandlung von Funktionsstörungen der niedrigen Harnwege
JP5319920B2 (ja) * 2004-09-10 2013-10-16 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
CN101472880B (zh) 2006-06-19 2013-04-24 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
PL2155663T3 (pl) 2007-06-15 2018-06-29 Newron Pharmaceuticals S.P.A. Podstawione pochodne 2-[2-(fenylo)etyloamino]alkanoamidu oraz ich zastosowanie jako modulatorów kanałów sodowych i (lub) wapniowych
EA019898B1 (ru) 2007-12-11 2014-07-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты
BR112012027623B1 (pt) 2010-04-27 2021-07-06 Newron Pharmaceuticals S.P.A. Processo para a produção de sais de ralfinamida metanossulfonato ou seus renantiômeros, forma pseudopolimorfa de hemi-hidrato cristalino h do sal de metanossulfonato de ralfinamida, ou seu r-enantiômero, seu uso e formulação farmacêutica que o compreende
RU2449805C1 (ru) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
DE102012108965B4 (de) 2012-09-24 2014-08-14 Exscitron Gmbh Stromquelle mit verbesserter Dimmvorrichtung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
SE9801494D0 (sv) * 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
RU2164512C1 (ru) * 1999-07-27 2001-03-27 Всероссийский научный центр по безопасности биологически активных веществ Производные аминокислот, проявляющие антиаритмическую активность
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US20020042405A1 (en) * 2000-07-27 2002-04-11 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
CA2459470C (en) * 2001-09-03 2010-10-12 Patricia Salvati Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
DE60219687T2 (de) * 2001-12-27 2007-12-27 Ortho-Mcneil Pharmaceutical, Inc. Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
EP1438956A1 (de) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
NZ545502A (en) * 2003-08-25 2010-04-30 Newron Pharm Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (de) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
JP5319920B2 (ja) * 2004-09-10 2013-10-16 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
EP1870097A1 (de) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen
CN101472880B (zh) * 2006-06-19 2013-04-24 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
PL2155663T3 (pl) * 2007-06-15 2018-06-29 Newron Pharmaceuticals S.P.A. Podstawione pochodne 2-[2-(fenylo)etyloamino]alkanoamidu oraz ich zastosowanie jako modulatorów kanałów sodowych i (lub) wapniowych
EA019898B1 (ru) * 2007-12-11 2014-07-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты
KR101500962B1 (ko) * 2007-12-19 2015-03-10 뉴론 파마슈티칼즈 에스. 피. 에이. 정신 장애의 치료에 유용한 알파­아미노아미드 유도체

Also Published As

Publication number Publication date
RU2396251C2 (ru) 2010-08-10
DK1658062T3 (da) 2010-05-31
JP2007503424A (ja) 2007-02-22
WO2005018627A1 (en) 2005-03-03
ES2339021T3 (es) 2010-05-14
SI1658062T1 (sl) 2010-05-31
EP1658062A1 (de) 2006-05-24
AU2004266494B2 (en) 2010-04-08
KR101233711B1 (ko) 2013-02-18
AU2004266494A1 (en) 2005-03-03
CA2536764C (en) 2013-09-17
EP1658062B1 (de) 2010-02-17
PT1658062E (pt) 2010-03-31
JP5042625B2 (ja) 2012-10-03
KR20060128825A (ko) 2006-12-14
US20100016440A1 (en) 2010-01-21
IL173886A0 (en) 2006-07-05
NO20060896L (no) 2006-03-09
RU2006105634A (ru) 2006-08-10
CN1842328A (zh) 2006-10-04
CY1109992T1 (el) 2014-09-10
PL1658062T3 (pl) 2010-07-30
CA2536764A1 (en) 2005-03-03
NZ545502A (en) 2010-04-30
NO335245B1 (no) 2014-10-27
IL173886A (en) 2012-09-24
DE602004025586D1 (de) 2010-04-01
WO2005018627A8 (en) 2005-09-01
BRPI0413982A (pt) 2006-11-07
US20070276046A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NO20081636L (no) FAP - inhibitorer
NO20071127L (no) Triazoloftalaziner
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200701799A1 (ru) Транс-каротиноиды, синтез указанных каротиноидов, получение композиций и их применение
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE400567T1 (de) Kinaseinhibitoren
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1658062

Country of ref document: EP